Chris Chapman, M.D.

Chris Chapman, M.D.

Cofounder, Chairman, and Chief Executive Officer

Chris Chapman, M.D. serves as an appointed a director for MIRA Pharmaceuticals Inc. Prior to joining MIRA Pharmaceuticals Inc., and since 2015, Dr. Chapman serves as the current President, Chief Medical Officer and Director of MyMD Pharmaceuticals, Inc., and since 1999, Dr. Chapman has also served as the Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., a consulting organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues. In addition, from 2003-2004, Dr. Chapman served as the Associate Director of Drug Safety, Pharmacovigilance, and Clinical Operations for Organon Pharmaceuticals, where he was responsible for the supervision of four fellow M.D.s and 10 drug safety specialists.

Prior to his time at Organon, Dr. Chapman served as Director, Medical Affairs, Drug Safety and Medical Writing Departments at Quintiles (currently known as IQVIA), from 1995-2003, where he grew the division from no employees to forty employees, including eight board certified physicians, four RNs, two pharmacists, eight medical writers and supporting staff. Dr. Chapman has also served on the board of directors of Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.) from 2007-2016, including as a member of the Audit Committee from 2007-2014, chairperson of the Compensation Committee from 2007-2014, and chairperson of the Executive Search Committee from 2007 to 2014. Dr. Chapman is an experienced executive and global medical expert, and has extensive experience in providing monitoring and oversight for ongoing clinical trials including both adult and pediatric subjects.

Dr. Chapman is also the founder of the Chapman Pharmaceutical Health Foundation, an IRS Section 501(c)(3) nonprofit organization established to solicit public funds and to support healthcare needs such as AIDS, diabetes, hypertension, lupus, sickle cell anemia, malaria and tuberculosis, which was organized in 2006. Dr. Chapman is a graduate of the Harvard Kennedy School of Cambridge, Massachusetts for financial management in 2020. Dr. Chapman received his M.D. degree from Georgetown University in Washington, D.C. in 1987, and completed his internship in Internal Medicine, a residency in Anesthesiology and a fellowship in Cardiovascular and Obstetric Anesthesiology at Georgetown. Prior to his time at Georgetown, Dr. Chapman served in the air force as a B-52 crew chief in the Vietnam era.

Craig Eagle, M.D.

Craig Eagle, M.D.

Director

Craig Eagle, M.D. is currently the Vice President of Oncology for Genentech, a position he has held since 2019, where he oversees the medical programs across Genentech’s oncology portfolio. Prior to his current role, Dr. Eagle worked in several positions at Pfizer from 2009 to 2019, including as the oncology business lead in the United Kingdom and Canada, the global lead for Oncology Strategic Alliances and Partnerships based in New York, and as the head of the Oncology Therapeutic Area Global Medical and Outcomes Group, including the U.S. oncology medical business. Through his multiple roles at Pfizer, Dr. Eagle delivered significant business growth and was involved in multiple strategic acquisitions and divestitures. In addition, while at Pfizer, Dr. Eagle oversaw extensive oncology clinical trial programs, multiple regulatory and payer approvals across Pfizer’s oncology portfolio, health outcomes assessments and scientific collaborations with key global research organizations like the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC), and led worldwide development of several compounds including celecoxib, aromasin, irinotecan, dalteparin and ozagomicin.

Dr. Eagle has served as a member of the Scientific Advisory Board at Generex Biotechnology Corporation (OTCQB: GNBT), a publicly-traded integrated healthcare holding company, since August 2010 and as a member of the company’s board of directors since 2017, and also currently serves as a member of the board of directors and chair of the Science and Policy Committee of Pierian Biosciences, a privately held life sciences company.

Dr. Eagle attended Medical School at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney and was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his training, Dr. Eagle performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets before moving into the pharmaceutical industry.

Hugh McColl

Hugh McColl

Director

Hugh currently serves as a Partner at Collwick Capital, a boutique alternative investment firm. Before founding Collwick Capital, he spent 14 years in the hedge fund industry. Hugh was a private investments portfolio manager for Round Table Investment Management and McColl Brothers Lockwood, served as the COO for M&M Partners and was the CEO and Portfolio Manager for McColl Partners. From 1991 to 1996, Hugh served as the President of The Shelton Companies.

Hugh is a graduate of the University of North Carolina and received an MBA from the University of Virginia Darden School of Business. He currently serves on the Board of Directors of Fintag Holdings, Inc. and of Heritage Brands, Inc. and is a Senior Advisor to Brown Brothers Harriman’s Capital Partners Group.

Talhia Tuck

Talhia Tuck

Director

Talhia Therese Tuck is currently serving as the Program Project Director of Georgetown Law School’s Innovative Policing Program since November 2019 as its first Program Associate. Prior to holding this position, she was an Associate Director of Admissions at Georgetown University for four years, where she evaluated applications for the undergraduate schools; served as the admissions representative for multiple regions; and chaired several admissions committees. In this role, she also served on numerous educational panels and conducted outreach in the Washington, D.C. area.

Before joining the Georgetown University community, Talhia worked in the investment relations and communications field, where she served as Vice President for Communications and Investor Relations at a healthcare company. In this capacity, she was responsible for coordinating communications with shareholders, the financial community, and the media. In addition to her communications experience, Talhia also has experience working in the legal field. Following her graduation from law school, she participated in the Ropes & Gray New Alternatives Program as a Fellow at the Office of the State’s Attorney for Montgomery County, Maryland. Subsequently, she worked in the Corporate Department at Ropes & Gray in Washington, DC.

Prior to attending law school, Talhia was a journalist with MSNBC, NBC News, ABC News, and the CBS affiliate, WINK-TV. She also worked as an admissions officer for Harvard College at Harvard University. Immediately after graduating from college, Talhia worked as a financial analyst at Goldman Sachs in the Investment Management Division. Talhia received her A.B. from Harvard College, cum laude, and received her J.D. from Harvard Law School

Michael Jerman

Michael Jerman

Director

Michael Jerman, CPA joined our company as a director in November 2023. He also serves as a member of the board of directors of Inhibitor Therapeutics, Inc. (OTC:INTI). Mr. Jerman has served as the managing partner at Hollywell Partners, a professional accounting and finance consulting firm, since May 2019, and has provided chief financial officer and other services to multiple private equity-backed companies in the energy, SaaS, and manufacturing industries. Prior to his role with Hollywell Partners, he was a Director with PwC in the US and UK from January 2007 to August of 2019 and was a Captain with the United States Air Force from July 2003 to June 2015. He has led global public and private client engagements in the industries of retail and consumer, energy, utilities and mining, and transportation and logistics. Mr. Jerman has significant experience in client equity and debt offerings, business combinations inclusive of public listing and reporting requirements, initial valuations and ongoing goodwill impairment analyses, share-based awards, restructuring, and global taxes, as well as stakeholder management, specifically with board and management presentation experience to include annual and quarterly requirements, fee negotiations, technical accounting and finance discussions, and fraud and non-compliance investigations. Mr. Jerman has specialized in rapid project mobilization and deployment of skilled resources for emergency issues, design, and implementation of small to large scale assurance requirements and advisory projects. Mr. Jerman’s additional experience includes leading PwC’s data acquisition methods and tools, client acquisitions and systems implementations to include new SOX-compliant control plan implementations across multiple systems, leading co-sourced internal audit projects, and time spent driving PwC’s lean efficiency initiatives. Mr. Jerman was a member of the PwC national office within the SEC PCAOB quality group supporting Europe and the EMEA regions with complex accounting and audit consultations. He earned a B.S. in accounting from the University of South Florida, an M.S. in accounting from the University of Tampa, and an M.B.A. from the University of Oxford.

Bradley Kroenig

Bradley Kroenig

Director

Brad Kroenig has been a Director of MIRA Pharmaceuticals since November 2021. He served as a business and strategy consultant for many private equity firms. He specializes in investor relations and raising seed capital for
startups. He is an experienced investor and business executive with significant experience in collaborating with executive-level and cross-functional teams, analyzing business situations, and developing and implementing practical investor strategies. Prior to his business career, Brad was one of the world’s leading fashion models. He was the face of Ralph Lauren, Gap, Tommy Hilfiger, Chanel, Fendi, and many other top brands. Models.com ranked him the #1 male model in the world from 2004 to 2006, and Vogue magazine ranked him the #3 male model of all time. Brad attended Florida International University on a NCAA Division I soccer scholarship.

Christos Nicholoudis, Esq.

Christos Nicholoudis, Esq.

General Counsel

In addition to his role as General Counsel for Telomir Pharmaceuticals, Christos Nicholoudis also serves as a Director and is the General Counsel for Mira Pharmaceuticals, NASDAQ (MIRA).  A former public defender for the 12th Judicial Circuit for the State of Florida from 2019 to 2022, Mr. Nicholoudis developed invaluable courtroom and trial experience. After his employment with the State, Mr. Nicholoudis started his own solo practice in February 2022, where he handles a wide range of legal matters including contract work, personal injury, real estate, wills trusts and estates and criminal law. He is licensed to practice law in Florida, New York, Texas and Washington D.C. and is fluent in Greek, Russian and Hebrew. Mr. Nicholoudis graduated from Cornell University with a B.S. and received his J.D. from Stetson College of Law.

Prior to his legal career, Mr. Nicholoudis worked in the hospitality industry where he owned and operated a restaurant in Bradenton Florida from 2012 to 2020 while simultaneously working on developing a 5-star hotel in Mykonos Greece with his family. Outside of the office Mr. Nicholoudis is a classically trained tenor and avid community theater performer.